The Clinical Study of Pitavastatin Treatment for Group of Mild to Moderate Alzheimer's Disease (PIT-ROAD)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00548145
Recruitment Status : Terminated
First Posted : October 23, 2007
Results First Posted : June 14, 2012
Last Update Posted : June 14, 2012
Kowa Company, Ltd.
Information provided by (Responsible Party):
Hiroaki Kazui, Osaka University

Brief Summary:
Some studies suggest that statin medications may be effective against Alzheimer's disease. However, this has not been proven. The purpose of this study is to evaluate the efficacy of pitavastatin in patients with mild to moderate Alzheimer's disease and hypercholesterolemia.

Condition or disease Intervention/treatment Phase
Alzheimer Disease Hypercholesterolemia Drug: Pitavastatin Drug: cholesterol-lowering medicine other than statin(e.g.,Ezetimibe,Colestimide) Not Applicable

Detailed Description:

The PIT-ROAD study will include 50 patients who have taken donepezil more than 3 months stably. This study will see how the use of a particular statin medication, pitavastatin, affects ADAS-Jcog score etc. and cholesterol.

Participants will be given a full information of the study and written informed consent should be obtained before entering the study. Participants will take part in 5 visits over the course of 12 months. If participants have taken cholesterol lowering drug, they will have wash-out period at least 4weeks. Participants will undergo 8 tests (ADAS-Jcog etc., baseline and month 12 visits), complete a medical history questionnaire (baseline), complete medication side effect review through questionnaire and/or blood sample (all visits). Participants will be randomly assigned to receive either pitavastatin or other cholesterol lowering medication for 12 months.

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 38 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Study Start Date : November 2007
Actual Primary Completion Date : October 2011
Actual Study Completion Date : March 2012

Arm Intervention/treatment
Experimental: 1 Drug: Pitavastatin
2 mg by orally/day Duration: 12 months

Active Comparator: 2 Drug: cholesterol-lowering medicine other than statin(e.g.,Ezetimibe,Colestimide)
duration: 12 months

Primary Outcome Measures :
  1. Alzheimer's Disease Assessment Scale-cognitive Component-Japanese Version(ADAS-Jcog) [ Time Frame: baseline and 12 months ]
    Alzheimer's Disease Assessment Scale-cognitive component-Japanese version is a cognitive test for Alzheimer's disease. This test includes some aspects that assess memory ,orientation, language, praxis, and so on. The possible range of this test is 0-70 points.Higher total points indicate more impairment.

Secondary Outcome Measures :
  1. MMSE, Neuropsychiatric Inventory, GDS-15, Zarit Burden Scale, Physical Self-Maintenance Scale, IADL, Everyday Memory Checklist, TC, HDL-C, Non HDL-C*, Apo A1, Apo B, Apo E *: Non HDL-C = (TC) - (HDL-C) [ Time Frame: baseline and 12 months ]
    Mini-Mental State Examination(MMSE),Geriatric Depression Scale-15(GDS-15),Instrumental Activities of Daily Living Scale(IADL),Total Cholesterol(TC)

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   20 Years to 85 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Alzheimer's Disease patients (15 ≤ MMSE total score ≤ 23, CDR "1" or "2")
  • Patients with hypercholesterolemia
  • Patients who have taken donepezil more than 3 months stably
  • Both patients and care-givers must be more than 20 years old

Exclusion Criteria:

  • Women with pregnancy or breast-feeding
  • Malignant tumor
  • Cerebrovascular disorder or myocardial infarction prior to 12 weeks
  • Heart failure [New York Heart Association (NYHA) class III or IV]
  • Hepatic or renal dysfunction
  • Severe hypertension
  • Hypothyroidism, hereditary muscular disease, history of drug-induced myopathy
  • Current involvement in another investigational drug study
  • Alcoholism, drug abuse

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00548145

Osaka University Hospital
Suita, Osaka, Japan, 565-0871
Sponsors and Collaborators
Osaka University
Kowa Company, Ltd.
Principal Investigator: Hiroaki Kazui, Ph.D. Osaka University Hospital

Additional Information:
Responsible Party: Hiroaki Kazui, M.D.Ph.D, Osaka University Identifier: NCT00548145     History of Changes
Other Study ID Numbers: OSK-07098
First Posted: October 23, 2007    Key Record Dates
Results First Posted: June 14, 2012
Last Update Posted: June 14, 2012
Last Verified: May 2012

Keywords provided by Hiroaki Kazui, Osaka University:
Alzheimer's Disease
Alzheimer Disease (MMSE 15-23 and CDR1 or 2)

Additional relevant MeSH terms:
Alzheimer Disease
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Neurodegenerative Diseases
Neurocognitive Disorders
Mental Disorders
Lipid Metabolism Disorders
Metabolic Diseases
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Anticholesteremic Agents
Hypolipidemic Agents
Molecular Mechanisms of Pharmacological Action
Enzyme Inhibitors
Lipid Regulating Agents